Champions Oncology, Inc.(CSBR)Earnings, Financials & Key Ratios
CSBR•NASDAQ
$6.63
20.1× P/E·Price updated Jun 27, 2026
AboutChampions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.Show more
- Revenue$57M+13.5%
- EBITDA$6M+228.3%
- Net Income$5M+164.6%
- EPS (Diluted)0.33+161.1%
- Gross Margin47.27%+14.2%
- EBITDA Margin11.39%+213.0%
- Operating Margin8.51%+161.7%
- Net Margin8.26%+156.9%
- ROE503.05%+194.5%
CSBR Price & Volume
Champions Oncology, Inc. (CSBR) stock price & volume — 10-year historical chart
Loading chart...
Volatile Service Revenue Masks Structural Liquidity Risks
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Mixed
Profitability:Strained
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Biotech funding cycle sensitivity
Key Thesis Takeaways
- Champions Oncology faces a challenging outlook defined by extreme revenue lumpiness, as evidenced by the 100% revenue decline in 2026Q3 compared to prior periods.
- While the company possesses a unique proprietary PDX library, its reliance on project-based contracts leaves it highly sensitive to biotech funding cycles and FDA regulatory shifts.
- Investors should remain cautious given the persistent thin equity base of $4.3 million and the company's inability to maintain consistent operating profitability.
Verdict Logic
the company's inability to sustain positive operating margins, highlighted by the $276,000 operating loss in 2026Q3, suggests significant execution risk in its current service-based business model.
CSBR Growth Metrics
Champions Oncology, Inc. (CSBR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years20.44%
5 Years12.13%
3 Years5.06%
TTM-29.37%
Profit CAGR
10 Years-
5 Years-
3 Years104.71%
TTM-135.01%
EPS CAGR
10 Years-
5 Years-
3 Years104.3%
TTM-136.46%
Return on Capital
10 Years-182.81%
5 Years-5.85%
3 Years-11.91%
Last Year74.09%
Peers Comparison
Key metrics vs top competitors for Champions Oncology, Inc. (CSBR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.63 | $92.87M | 20.09 | 13.54% | 8.26% | 503.05% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $0.15 | $2.33M | -0.06 | -15.77% | -183.93% | — | — | |
| $4.70 | $190.82M | 3.85 | 36.55% | -19.55% | -3.39% | — | |
| $551.50 | $43.8B | 42.16 | 10.42% | 24.63% | 70.87% | — | |
| $261.91 | $37.51B | -172.31 | 35.9% | -9.05% | -15.13% | — |
Compare CSBR vs Peers
Champions Oncology, Inc. (CSBR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CSBR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CSBR Frequently Asked Questions
Champions Oncology, Inc. (CSBR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Champions Oncology, Inc.'s revenue?
Champions Oncology, Inc. (CSBR) reported $41.4M in revenue for fiscal year 2025. This represents a 1834% increase from $2.1M in 1996.
How fast is Champions Oncology, Inc. growing?
Champions Oncology, Inc. (CSBR) grew revenue by 13.5% over the past year. This is steady growth.
Is CSBR profitable?
Champions Oncology, Inc. (CSBR) reported a net loss of $2.3M for fiscal year 2025.
Dividend & Returns
What is CSBR's return on equity?
Champions Oncology, Inc. (CSBR) has a return on equity (ROE) of 503.0%. This is excellent, indicating efficient use of shareholder capital.
What is Champions Oncology, Inc.'s free cash flow?
Champions Oncology, Inc. (CSBR) generated $3.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.